


CSIR, India's Technology

FELUDA: FnCas9 Editor Linked Uniform Detection Assay (Diagnostics)

- Paper Based Diagnostic based on CRISPR-Cas
- Broad reach, simpler, less set up cost, visual detection
- Independent Validation Completed
- Technology can be adopted for other diseases
- Approved by DCGI, the regulatory authority of India





CSIR-Institute of Genomics and
Integrative Biology (CSIR-IGIB)
New Delhi, India

#CSIRFightsCOVID19

CSIR, India's Technology: FELUDA

- FnCas9 Editor Linked Uniform Detection Assay (FELUDA) employs a highly accurate enzymatic readout for detecting nucleotide sequences, identifying nucleobase identity and inferring zygosity with precision.
- Detection of pathogenic sequences or variants in DNA and RNA through a point-of-care diagnostic approach is useful for rapid clinical prognosis.
- The output can be adapted to multiple signal detection platforms and can be quickly designed and deployed for versatile applications including rapid diagnosis of infectious diseases such as COVID-19.
- The knowledgebase encompasses a comprehensive pipeline including protein expression, sgRNA design, preparation of RNA complexes, detection methods that are dependent on applications, SOPs for pathogen detections, SNP detections.
- This technology has application in fast diagnosis nucleic acid based detection including genomic variations, diseases associated with the variations, pathogens, food contaminants, fish, poultry, cattle qualities.

FnCas9 Editor Linked Uniform Detection Assay (FELUDA)



Laboratory/Institute

CSIR-Institute of Genomics & Integrative Biology (CSIR-IGIB)



Industry Partner

Tata Sons Ltd

#CSIRFightsCOVID19